comparemela.com

Latest Breaking News On - Intensity therapeutics - Page 3 : comparemela.com

Portage Biotech Reports Results for Fiscal Quarter Ended

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development.

United kingdomUnited statesIan waltersPortage biotech incCompany board of directorsCompany annual report on formTrial safety committeeOwners of the companySociety for immunotherapy of cancerAmerican society of clinical oncologyClinical oncologyAnnual meetingChief executive officerQuarter ended decemberRegistered direct offeringIntensity therapeutics

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

WESTPORT, Conn., Feb. 28, 2024 Portage Biotech Inc. , a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported.

United kingdomUnited statesIan waltersCompany board of directorsTrial safety committeeCompany annual report on formOwners of the companyGlobenewswire incSociety for immunotherapy of cancerAmerican society of clinical oncologyPortage biotech incClinical oncologyAnnual meetingChief executive officerSafety committeeQuarter ended

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of.

New yorkUnited statesLewish benderMarriott marquisJustin kulikIntensity therapeutics incIntensity therapeuticsChief executive officerNew york marriott marquisRelations contactIntensity therapeutics incHealth care amp hospitalsMedical pharmaceuticalsConference call announcementsClinical trials amp medical discoveries

Intensity Therapeutics Gets FDA Green Light for Phase 3 Study

By Colin Kellaher Intensity Therapeutics has received U.S. Food and Drug Administration approval to launch a Phase 3 study of its lead drug candidate.

Colin kellaherDrug administrationArticle normalBiotechnology servicesCancer drugsHealthcare life sciencesSpecialized drugs medicationsRegulation government policyNew products servicesResearch developmentProduct service approvalsCorporate industrial newsProducts servicesNew product service testingPolitical general newsMedical conditions

Intensity Therapeutics To Initiate Phase 3 Sarcoma Trial In H1

Intensity Therapeutics, Inc. (INTS) issued a business update on its phase 3 sarcoma clinical program. In the fourth quarter, the company submitted a new IND to the FDA which included the phase 3 protocol for a superiority trial of the lead product INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes.

United statesFlorida keysUnited launch allianceInstitute for supply managementSupply managementLaunch allianceSpace launchCape canaveral space force stationFlorida straitsCoast guardBorder protection airMarine operationsIntensity therapeutics

vimarsana © 2020. All Rights Reserved.